Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Tirzepatide

A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

Eli Lilly · Phase 2 · Active, not recruiting · Enrollment 252

NCT06643728

ArmPopulationDoseWeeksEstimandWeight change
Part A: Bimagrumab Dose 2 + Tirzepatide PlaceboObesity or overweightn/rn/rn/rn/r
Part A: Bimagrumab Placebo + Tirzepatide Dose 1Obesity or overweightn/rn/rn/rn/r
Part A: Bimagrumab Placebo + Tirzepatide Dose 2Obesity or overweightn/rn/rn/rn/r
Part A: Bimagrumab Dose 1 + Tirzepatide Dose 1Obesity or overweightn/rn/rn/rn/r
Part A: Bimagrumab Dose 1 + Tirzepatide Dose 2Obesity or overweightn/rn/rn/rn/r
Part A: Bimagrumab Dose 2 + Tirzepatide Dose 2Obesity or overweightn/rn/rn/rn/r
Part A: Bimagrumab Placebo + Tirzepatide PlaceboObesity or overweightn/rn/rn/rn/r
Part B: Bimagrumab Dose 2 (no titration) + Tirzepatide Dose 1Obesity or overweightn/rn/rn/rn/r
Part B: Bimagrumab Dose 2 (fast titration) + Tirzepatide Dose 1Obesity or overweightn/rn/rn/rn/r
Part B: Bimagrumab Dose 2 (slow titration) + Tirzepatide Dose 1Obesity or overweightn/rn/rn/rn/r
Part B: Bimagrumab Dose 1 + Tirzepatide PlaceboObesity or overweightn/rn/rn/rn/r
Part B: Bimagrumab Placebo + Tirzepatide PlaceboObesity or overweightn/rn/rn/rn/r